Study: Copanlisib + rituximab slows relapsed indolent lymphoma
Combating vaccine resistance: Modern questions with a long history
14 April 2021Mix up your exercise routine and see big results
14 April 2021Study: Copanlisib + rituximab slows relapsed indolent lymphoma
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association for Cancer Research, held virtually from April 10 to 15.
